The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)
Open accessPublished version of a preprint
Abstract
Significance: Intracellular proteins interact with each other to perform functions that are critical to normal and disease states. Attempts at altering pathological protein–protein interactions with traditional approaches have largely failed. Here, we explore an emerging approach we call “bioPROTACs”—engineered fusion proteins that consist of a target binding domain and an E3 ligase, an arrangement that results in the specific degradation of the therapeutic target. Our systematic study shows bioPROTAC design requirements are highly flexible in terms of both the binding domain and E3 ligase components. Resulting molecules can be used as powerful tools for uncovering biology, informing on the design of small molecule target degraders (e.g. PROTACs), and, if delivery issues can be addressed, potential therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The platform has been used to generate GFP-degrading bioPROTACs based on various E3 ligases: the CUL1 ligases β-TRCP, F-box and WD repeat domain-containing 7 (FBW7) and SKP2; the CUL2 ligase VHL; the CUL3 ligase speckle type BTB/POZ protein (SPOP); the CUL5 ligases suppressor of cytokine signalling 2 (SOCS2) and ankyrin repeat and SOCS box-containing 1 (ASB1); and the U-box E3 ligase CHIP.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [214]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
PCNA, the Maestro of the Replication Fork
Moldovan, G.-L., Pfander, B., & Jentsch, S. (2007) · Cell · doi:10.1016/j.cell.2007.05.003 · Cited by 1,796
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
The dTAG system for immediate and target-specific protein degradation
Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923
Targeting and tracing antigens in live cells with fluorescent nanobodies
Rothbauer, U., Zolghadr, K., Tillib, S. V., Nowak, D., Schermelleh, L., Gahl, A., Backmann, N., Conrath, K., Muyldermans, S., Cardoso, M. C., et al. (2006) · Nature Methods · doi:10.1038/nmeth953 · Cited by 715
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517
Fluorescent fusion protein knockout mediated by anti-GFP nanobody
Caussinus, E., Kanca, O., & Affolter, M. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2180 · Cited by 510
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Churcher, I. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01272 · Cited by 491 · cited 1×
“Second, molecules can be recycled for multiple rounds of degradation, a substoichiometric property which is especially useful for high-abundance targets compared to stoichiometric inhibitors may become limited by the high systemic doses required and corresponding polypharmacologybased toxicities (4).”
BackgroundHaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
Buckley, D. L., Raina, K., Darricarrere, N., Hines, J., Gustafson, J. L., Smith, I. E., Miah, A. H., Harling, J. D., & Crews, C. M. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00442 · Cited by 488
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437
Drugging the undruggables: exploring the ubiquitin system for drug development
Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427 · cited 1×
“First, degradation can be induced via interaction sites across the POI surface, regardless of whether the binding site is of functional consequence (2), thus expanding the chemical space for tackling otherwise intractable targets (3).”
BackgroundEdmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422
Regulation of PCNA–protein interactions for genome stability
Mailand, N., Gibbs‐Seymour, I., & Bekker‐Jensen, S. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3562 · Cited by 395
Cullin-RING ubiquitin ligases: global regulation and activation cycles
Bosu, D. R., & Kipreos, E. T. (2008) · Cell Division · doi:10.1186/1747-1028-3-7 · Cited by 318
PCNA: a silent housekeeper or a potential therapeutic target?
Wang, S.-C. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.02.004 · Cited by 285
PCNA Is a Cofactor for Cdt1 Degradation by CUL4/DDB1-mediated N-terminal Ubiquitination
Senga, T., Sivaprasad, U., Zhu, W., Park, J. H., Arias, E. E., Walter, J. C., & Dutta, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512705200 · Cited by 250
Saerens, D., Pellis, M., Loris, R., Pardon, E., Dumoulin, M., Matagne, A., Wyns, L., Muyldermans, S., & Conrath, K. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.038 · Cited by 240
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228
Koide, A., Wojcik, J., Gilbreth, R. N., Hoey, R. J., & Koide, S. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.019 · Cited by 227
Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Gechijian, L. N., Buckley, D. L., Lawlor, M. A., Reyes, J. M., Paulk, J., Ott, C. J., Winter, G. E., Erb, M. A., Scott, T. G., Xu, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0010-y · Cited by 222
Higher‐order oligomerization promotes localization of SPOP to liquid nuclear speckles
Marzahn, M. R., Marada, S., Lee, J., Nourse, A., Kenrick, S. A., Zhao, H., Ben‐Nissan, G., Kolaitis, R., Peters, J. L., Pounds, S. B., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201593169 · Cited by 206
Regulation of proliferating cell nuclear antigen ubiquitination in mammalian cells
Niimi, A., Brown, S. E., Sabbioneda, S., Kannouche, P. L., Scott, A., Yasui, A., Green, C., & Lehmann, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802727105 · Cited by 171
Harnessing the Ubiquitination Machinery to Target the Degradation of Specific Cellular Proteins
Zhou, P., Bogacki, R., McReynolds, L., & Howley, P. M. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00074-5 · Cited by 164
Guharoy, M., Bhowmick, P., Sallam, M., & Tompa, P. (2016) · Nature Communications · doi:10.1038/ncomms10239 · Cited by 145
Collins, I., Wang, H., Caldwell, J., & Chopra, R. (2017) · Biochemical Journal · doi:10.1042/bcj20160762 · Cited by 139
Kontopidis, G. A., Wu, S., Zheleva, D. I., Taylor, P., McInnes, C., Lane, D. P., Fischer, P. M., & Walkinshaw, M. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406540102 · Cited by 128
Self-citationIdentification of a novel nuclear speckle‐type protein, SPOP
Nagai, Y., Kojima, T., Muro, Y., Hachiya, T., Nishizawa, Y., Wakabayashi, T., & Hagiwara, M. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01340-9 · Cited by 124
Nanobody-targeted E3-ubiquitin ligase complex degrades nuclear proteins
Shin, Y. J., Park, S. K., Jung, Y. J., Kim, Y. N., Kim, K. S., Park, O. K., Kwon, S., Jeon, S. H., Trinh, L. A., Fraser, S. E., et al. (2015) · Scientific Reports · doi:10.1038/srep14269 · Cited by 112
Xu, B., Hua, J., Zhang, Y., Jiang, X., Zhang, H., Ma, T., Wei, Z., Sun, R., Shen, W. D., Sha, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016046 · Cited by 110
An affinity-directed protein missile system for targeted proteolysis
Fulcher, L. J., Macartney, T., Bozatzi, P., Hornberger, A., Rojas-Fernandez, A., & Sapkota, G. P. (2016) · Open Biology · doi:10.1098/rsob.160255 · Cited by 91
Zheleva, D. I., Zhelev, N., Fischer, P. M., Duff, S. V., Warbrick, E., Blake, D., & Lane, D. P. (2000) · Biochemistry · doi:10.1021/bi992498r · Cited by 86
Self-citationPortnoff, A. D., Stephens, E. A., Varner, J. D., & DeLisa, M. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.544825 · Cited by 83
Brauchle, M., Hansen, S., Caussinus, E., Lenard, A., Ochoa‐Espinosa, A., Scholz, O., Sprecher, S. G., Plückthun, A., & Affolter, M. (2014) · Biology Open · doi:10.1242/bio.201410041 · Cited by 83
A protein knockdown strategy to study the function of β-catenin in tumorigenesis
Cong, F., Zhang, J., Pao, W. J., Zhou, P., & VARMUS, H. E. (2003) · BMC Molecular Biology · doi:10.1186/1471-2199-4-10 · Cited by 75
On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry
Long, M. J. C., Poganik, J. R., & Aye, Y. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b12608 · Cited by 73
Hatakeyama, S., Watanabe, M., Fujii, Y., & Nakayama, K. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1581 · Cited by 67
Chen, W., Lee, J., Cho, S. Y., & Fine, H. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3906 · Cited by 65
Eradication of pathogenic β-catenin by Skp1/Cullin/F box ubiquitination machinery
Su, Y., Ishikawa, S., Kojima, M., & Liu, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2133261100 · Cited by 58
Ubiquitination of PCNA and Its Essential Role in Eukaryotic Translesion Synthesis
Chen, J., Bozza, W. P., & Zhuang, Z. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9187-3 · Cited by 58
Yu, Y., Cai, J., Tu, B., Wu, L., Zhao, Y., Liu, X., Li, L., McNutt, M. A., Feng, J., He, Q., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.015289 · Cited by 57
Ma, Y., Gu, Y., Zhang, Q., Han, Y., Yu, S., Lu, Z., & Chen, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0650 · Cited by 55
Exploring the functional complexity of cellular proteins by protein knockout
Zhang, J., Zheng, N., & Zhou, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2233012100 · Cited by 54
Broad-Spectrum Proteome Editing with an Engineered Bacterial Ubiquitin Ligase Mimic
Ludwicki, M. B., Li, J., Stephens, E. A., Roberts, R. W., Koide, S., Hammond, P. T., & DeLisa, M. P. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00127 · Cited by 45
Specific GFP-binding artificial proteins (αRep): a new tool for in vitro to live cell applications
Chevrel, A., Urvoas, A., de la Sierra-Gallay, I. L., Nicaise, M., Moutel, S., Desmadril, M., Perez, F., Gautreau, A. M., TILBEURGH, H. V., Minard, P., et al. (2015) · Bioscience Reports · doi:10.1042/bsr20150080 · Cited by 43
Targeted degradation of β-catenin by chimeric F-box fusion proteins
Liu, J., Stevens, J., Matsunami, N., & White, R. L. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.035 · Cited by 42
Warbrick, E. (2005) · Oncogene · doi:10.1038/sj.onc.1209320 · Cited by 40
Cited by
Sorted by citations
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Ishida, T., & Ciulli, A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220965528 · Cited by 404
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective
Luh, L. M., Scheib, U., Juenemann, K., Wortmann, L., Brands, M., & Cromm, P. M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004310 · Cited by 201
Metadata
- Authors
- Lim, S., Khoo, R., Peh, K. M., Teo, J., Chang, S. C., Ng, S., Beilhartz, G. L., Melnyk, R. A., Johannes, C. W., Brown, C. J., Lane, D. P., Henry, B., & Partridge, A. W.
- Affiliations
- MSD (Singapore) (SG)
- Pacific Translational Biomarkers, MSD International, Singapore 138665;
- Hospital for Sick Children (CA)
- University of Toronto (CA)
- Agency for Science, Technology and Research (SG)
- Corresponding author
- Partridge, Anthony W.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-03-02
- Volume
- 117
- Issue
- 11
- Pages
- 5791-5800
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7084165
- OpenAlex
- W3010201122
- Cited by
- 170
- References
- 52
- Citations by year
- 2026: 30 · 2025: 38 · 2024: 35 · 2023: 26 · 2022: 18 · 2021: 15 · 2020: 8
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, targeted protein degradation, proliferating cell nuclear antigen, DNA synthesis, cell cycle progression, oncology drug targets
- MeSH terms
- Binding Sites, Humans, Protein Binding, Recombinant Proteins, Protein Engineering, Proliferating Cell Nuclear Antigen, Ubiquitin-Protein Ligases, HEK293 Cells, Molecular Targeted Therapy, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
